| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1375587 | Bioorganic & Medicinal Chemistry Letters | 2009 | 4 Pages |
Abstract
Glycine transporter 1 (GlyT1) represents a novel target for the treatment of schizophrenia via the potentiation of glutamatergic NMDA receptors. The discovery of 4,4-disubstituted piperidine inhibitors of GlyT1 which exhibit improved pharmacokinetic properties, including oral bioavailability, is discussed.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Scott E. Wolkenberg, Zhijian Zhao, David D. Wisnoski, William H. Leister, Julie O’Brien, Wei Lemaire, David L. Williams Jr., Marlene A. Jacobson, Cyrille Sur, Gene G. Kinney, Doug J. Pettibone, Philip R. Tiller, Sheri Smith, Christopher Gibson,